Latest News, Updates & Breaking Headlines
For Indian pharmaceutical exports, the US represents the primary market, comprising approximately 35% of total exports, with a value reaching about $10 billion in FY25. (AI image) US President Donald Trump’s move to impose 100% tariffs on branded and patented pharmaceutical exports has rattled Indian pharma stocks, even though most companies earn from US markets…
Several prominent Indian pharmaceutical firms, including Sun Pharma, Dr. Reddy’s Laboratories, Cipla, Lupin, Aurobindo Pharma, and Zydus Lifesciences, maintain substantial export operations to the USA. (AI image) Pharma stocks hit by Trump’s tariffs: Pharmaceutical stocks declined sharply by up to 5% on Friday, September 26, following US President Donald Trump’s declaration of imposing 100% tariffs…
US President Donald Trump on Friday announced a 100% tariff on pharma products, along with 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks starting on October 1.The announcements came in a series of posts on his social media platform indicating that he remains committed to tariffs beyond…
India’s pharmaceutical and healthcare industry is preparing for a significant wave of fundraising, with companies expected to raise Rs 12,000-13,000 crore through initial public offerings (IPOs) in the next six to nine months.According to ET, around 15 firms are likely to enter the primary market shortly. The Securities and Exchange Board of India (Sebi) has…
US stocks slipped on Monday as Wall Street took a breather following a string of record highs last week. The S&P 500 dipped 0.2%, the Dow Jones Industrial Average fell 228 points, or 0.5%, and the Nasdaq composite eased 0.1% as of 9:35 a.m. Eastern time, AP reported. All three indexes had hit fresh all-time…
India’s pharmaceutical market grew 8.1% in August as compared with the same month last year, according to data from IQVIA quoted in an HDFC Securities report. The growth follows a 7.1% rise in July and is close to the 8% pace seen through FY25. However, unit sales in August slipped 0.8%.The steady performance was led…
India’s pharmaceutical sector is projected to post healthy revenue growth of 7-9 per cent in FY26, aided by robust demand in the domestic and European markets, even as momentum in the United States is expected to cool, according to rating agency ICRA.The domestic market is expected to expand by 8-10 per cent and Europe by…
